# Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients

> **NCT01356602** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 397 (actual)

## Conditions studied

- Acute Gouty Arthritis

## Interventions

- **DRUG:** Canakinumab pre-filled syringe
- **DRUG:** Canakinumab lyophilized powder
- **DRUG:** Triamcinolone Acetonide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01356602
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2012-09
- **Final completion:** 2012-09
- **Target enrollment:** 397 (ACTUAL)
- **Last updated:** 2014-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01356602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01356602, "Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01356602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*